WASHINGTON, DC - (NewMediaWire) - November 4, 2015 - The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, today announced the release of its quarterly data report, offering an in-depth look at sector trends and metrics July through September 2015.
Using information provided by ARM's data partner Informa, the quarterly report details industry-specific statistics compiled from more than 580 leading therapeutics companies worldwide, including total financings, corporate partnerships and acquisitions, clinical trial information, key data events and ARM's current regulatory and legislative priorities.
New in this report is a section specifically highlighting cell therapy's clinical outlook, with perspectives from BrainStorm Cell Therapeutics, Pluristem Therapeutics, ReNeuron and TiGenix.
The report also features commentary from several sector investment analysts, including Adam Bristol, Aquilo Capital; Fariba Ghodsian, DAFNA Capital Management; and Daniel Krizek, Brookside Capital.
"The first three quarters of 2015 have seen significant dealmaking and financing activity sector-wide," said Morrie Ruffin, managing director of ARM. "Despite recent market volatility and downward pressure on biotech stocks across the board, there continues to be a high level of interest in this sector and a great deal of optimism in the clinical and commercial potential of gene and cell therapies and regenerative medicine."
Highlighted findings from the third quarter report include:
- Globally, companies in the combined regenerative medicine and advanced therapies field raised more than $9.3 billion in the first three quarters of 2015, up 163 percent when compared to the same time period last year. The report also includes additional financing data by technology group and financing type.
- There were 571 clinical trials underway worldwide at the close of Q3 2015.
- ARM's current regulatory and legislative priorities include advocating for reimbursement coverage and coding policies for regenerative medicine and advanced therapies products; inclusion of ARM's proposals in U.S. 21st Century Cures Act; PDUFA reauthorization; European Commission's GMP requirements for Advanced Therapies Medicinal Products and more.
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial, clinical trial information and data events.
The report is available online here. For more information, please visit alliancerm.org or contact ARM's Director of Communications Lyndsey Scull at email@example.com.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.